UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) April 3, 2006
ADVENTRX Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
| |
|
|
| 001-32157
|
|
84-1318182 |
| (Commission File Number)
|
|
(IRS Employer Identification No.) |
6725 Mesa Ridge Road, Suite 100
San Diego, California 92121
(Address of principal executive offices) (Zip Code)
(858) 552-0866
(Company’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
o Soliciting material pursuant to rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
TABLE OF CONTENTS
Item 8.01. Other Events.
On April 3, 2006, the Company announced that positive preclinical testing results showing
strong antiviral synergy without added cytotoxicity with combinations of Thiovir™ and zidovudine
(AZT) were presented at the HIV Pathogenesis Meeting in Keystone, Colorado on March 31, 2006.
On April 5, 2006, the Company announced that it presented preclinical study results showing an
improved toxicity profile for its oncology compound, ANX-530 (vinorelbine emulsion) at the American
Association for Cancer Research (AACR) 97th Annual Meeting 2006 on April 5, 2006.
The press releases issued by the Company on April 3 & 5, 2006 with respect to these matters
are included with this report as exhibits.
Item 9.01. Financial Statements and Exhibits.
|
|
|
| (99) |
|
(c) The exhibit list required by this item is incorporated by reference to the Exhibit Index
filed as part of this report. |